Evidence map›Paper›PMID 42260510›Full record

ArticleBMC psychiatry2026

Machine learning model to identify gut microbiome-derived metabolites as potential biomarkers of autism spectrum disorder: a pilot study.

Silvia Babolin, Roberto Enea, Mariagrazia Cicala, Daniele Di Giovanni, Luigi Mazzone, Leonardo Emberti Gialloreti

Abstract read
In one paragraph

Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Silvia BabolinChild Neurology and Psychiatry Unit, Department of Wellbeing of Mental and Neurological, Dental and Sensory Organ Health, Policlinico Tor Vergata Hospital, Viale Oxford, 00133, Rome, Italy. silviababolin.npi@gmail.com.
Roberto EneaIMME Research Centre, Via San Francesco d'Assisi 20, 81100, Caserta, Italy.
Mariagrazia CicalaDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Daniele Di GiovanniDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.
Luigi MazzoneChild Neurology and Psychiatry Unit, Department of Wellbeing of Mental and Neurological, Dental and Sensory Organ Health, Policlinico Tor Vergata Hospital, Viale Oxford, 00133, Rome, Italy.
Leonardo Emberti GialloretiDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Via Montpellier 1, 00133, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism Spectrum Disorder (ASD) arises from complex and not yet completely understood interactions between genetic and environmental factors. Alongside known hallmarks of neurobiological and structural changes in ASD brain, alterations in gut microbiota are frequently observed in ASD and may contribute to its pathophysiology. Identifying reliable biomarkers through multivariate analysis and machine learning offers promising avenues for improving ASD diagnosis and understanding comorbid gastrointestinal symptoms. In this study, a machine learning model was trained to identify ASD and healthy controls based on the theoretical production of metabolites for each gut bacterial species and each individual, combining the data collected from two global databases (GMRepo v2 and Agora2). Random Forest Classification models reach a mean accuracy of 85%, and a subsequent literature analysis of the 5% most significant metabolites showed a 40% correspondence with previously published in vivo studies. Some of the most relevant compounds detected by the theoretical model are amino acid and amino-acidic derivatives, volatile organic compounds, and short-chain fatty acids. Results are coherent with empirical evidence, supporting microbiota's role in ASD pathophysiology by contributing to neurotransmitters' biosynthesis and degradation, intestinal epithelial barrier integrity, immunological modulation. Future work will focus on stratified sampling, empirical validation, and developing personalized metabolic signatures for early diagnosis and precision medicine.

Indexed as

Autism Spectrum DisorderGastrointestinal MicrobiomeMachine LearningBiomarkersChildFemaleHumansMalePilot ProjectsBiomarkersASD biomarkerASD microbiomeAutismAutism spectrum disorderBrain–gut axisGut microbiomeMachine learningMetabolome

Identifiers

PMID42260510
PMCPMC13471347

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.